<DOC>
	<DOC>NCT00919880</DOC>
	<brief_summary>The purpose of this study is to determine whether neo-adjuvant weekly paclitaxel with carboplatin is better than paclitaxel alone in efficiency and safety in early breast cancer, and to explore whether ultrasound and magnetic resonance imaging can predict the efficiency of neo-adjuvant chemotherapy.</brief_summary>
	<brief_title>Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>female patients between 18 and 65 years old pathological diagnosed invasive breast cancer; medium and high risk primary breast cancer according to St. Gallen 2007 able and willing to give consent to participate in the study pregnant or lactating females previous treatment for breast cancer other tumor history instable complication (e.g., myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection allergy history to similar drugs concurrent disease or condition that would make the patient inappropriate for study participation resist to participate in the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>